Drug Trial Radar · NCT05016609
Same-visit Hepatitis C Testing and Treatment (The QuickStart Study)
Last checked: Nov 19, 2026Latest source record: Nov 13, 2023 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Status unknown
Enrollment
1,800
Planned (sponsor's estimate)
Start
Mar 9, 2022
Primary completion
Apr 2024
Study completion Jun 2024
Sponsor
- Lead sponsor
- Macfarlane Burnet Institute for Medical Research and Public Health LtdAcademic, hospital or other
- Sponsor type
- Academic, hospital or other
- First posted
- Aug 23, 2021
Design
- Study type
- Interventional
- Phase
- Phase 4
- Allocation
- Randomized
- Model
- Crossover
- Masking
- None
- Primary purpose
- Health services research
- FDA-regulated drug
- Yes
- Who can join
- All sexes, from 18 years
- Healthy volunteers
- Yes
Summary
As written by the sponsor on the registry.
The QuickStart study aims to assess the impact of three models of HCV care on HCV treatment uptake and cure among people who inject drugs. Rapid point-of-care (POC) HCV testing and test-and-treat strategies will be utilised in primary health care settings across Australia.
Conditions
- Hepatitis C
Interventions
OraQuick HCV Antibody test (OraSure Technologies, Inc)Device
The OraQuick HCV test is a point of care antibody test for detecting HCV antibodies in fingerstick blood. The test takes 20 minutes to provide a result. Appropriate pre- and post-test counselling will be provided to participants.
Xpert HCV Viral Load Finger-stick Point-of-Care test (Cepheid)Device
Xpert® HCV VL Fingerstick is an in vitro reverse transcription polymerase chain reaction (RT-PCR) assay for the detection and quantification of Hepatitis C Virus (HCV) RNA in human venous and capillary fingerstick EDTA whole blood. Only participants who return a reactive OraQuick HCV Antibody test will be offered the Xpert® HCV VL Fingerstick test. Appropriate pre- and post-test counselling will be provided to participants.
Sofosbuvir/Velpatasvir (Gilead)Drug
Participants with a detectable HCV antibody will be offered treatment with sofosbuvir/velpatasvir.
Primary outcomes
What the sponsor says the trial is designed to measure.
- HCV treatmentTime frame: Within 12 weeks of enrolment
- HCV cureTime frame: HCV cure will be measured between 4 and 20 weeks post treatment completion.
Locations
6 sites in 1 country. Site status is shown where the registry gives one.
Mediclinic Australia
Clayton South, Victoria, Australia · Recruiting
Innerspace
Collingwood, Victoria, Australia · Recruiting
Corio Community Health Centre
Corio, Victoria, Australia · Recruiting
Cohealth Fitzroy
Fitzroy, Victoria, Australia · Recruiting
Homeless Healthcare
Highgate, Western Australia, Australia · Recruiting
Cockburn Wellbeing
Success, Western Australia, Australia · Recruiting
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.